Leading expert in flow cytometry and systems biology. Senior bioinformatics scientist with a focus on exploratory immunological biomarker data analyses and long-standing experience in the pharmaceutical industry. Holds a doctorate in cell biology from Friedrich Miescher Institute in Basel, Switzerland.
Recognized industry leader focused on combining cutting-edge technology, strategic program design, and operational excellence to help life sciences companies effectively address the increasing evidence demands and need to accelerate research initiatives. Previous experience spans the execution of phase I-IV clinical trials, specialty lab services, biospecimen logistics and banking, risk management, and patient support initiatives.
Established industry leader focused on harnessing sane statistics for machine learning, bioinformatics, and R&D. Experienced in the entire pipeline from prototyping to deployment, always keeping overarching business and regulatory practices in mind. Passionate about succinct scientific communication to all stakeholders, leading to actionable insights.
Extensive industry expertise across the pharmaceutical and biotech space—translational research, data management, and statistical support—with a focus in precision medicine-guided efforts in drug and diagnostic development. Subject matter expert in genomics. Pioneered approaches in biomarker data management and has led Biometrics operations on over 70 clinical studies.
Noted bioinformatics expert across pharmaceutical and biotech industries. Focused on exploratory biomarker data analyses for the implementation of precision medicine. Specialized knowledge of operational management and biomarker data sciences. Former director of global bioinformatics at Merck Biopharma.
Respected expert in mathematics and fundamental and theoretical computer science. Strong focus on genetics. Developer of innovative bioinformatics algorithms for SNP analyses and genome-wide association studies. Avid proponent of and proactive contributor to the open source community.
Leading strategy expert in end-to-end bioinformatics and artificial intelligence solutions for biomarker-guided drug development, maximizing the value and utility of biomarker data in clinical trials, CDx, and diagnostics. Former CEO of SimplicityBio, holds a doctorate in molecular and cellular biology from the University of Lausanne.
Deep expertise in healthcare technology with a focus on using artificial intelligence to help biopharma and diagnostic companies solve the question, “Which therapy, when, and for which patient?” Extensive industry knowledge across the pharmaceutical and biotech space—translational informatics, biomarker R&D. Holds an MBA and is passionate about exploring interfaces between people and tech, effective communication, hiking, and sailing.
Extensive industry expertise across the pharmaceutical and biotech space—Dx regulatory submissions, translational informatics, biomarker R&D—with a focus in precision medicine-guided efforts as well as strategy development and medical device/diagnostic development. Globally responsible for translational informatics R&D efforts. Has led the development of novel methodologies for patient stratification and biomarker guided clinical trial design.
Extensive industry expertise across the pharmaceutical and biotech space—regulatory submissions, translational informatics, biomarker R&D—with a focus in precision medicine-guided efforts as well as strategy development and medical device/diagnostic development. Led numerous analytical R&D efforts and developed novel methodologies to harmonize and analyze data from high-throughput assays, translating it to value at the patient level.